Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Xilio Therapeutics announced initial clinical data from Phase 1C trial evaluating vilastobart combined with atezolizumab in advanced solid tumor patients. The combination showed promising anti-tumor activity, including two unconfirmed partial responses in patients with immunologically 'cold' tumors. A notable complete resolution of a metastatic liver lesion was observed in a patient with microsatellite stable colorectal cancer (MSS CRC). The treatment was generally well-tolerated, with no Grade 4 or 5 treatment-related adverse events reported. Initial Phase 2 data for the combination in metastatic MSS CRC patients is expected in Q4 2024.
Xilio Therapeutics (Nasdaq: XLO) reported Q3 2024 financial results and pipeline updates. The company will present initial Phase 1C data for vilastobart combined with atezolizumab at SITC Annual Meeting. Key financial metrics include cash position of $61.3 million, license revenue of $2.3 million, and net loss of $14.0 million. R&D expenses decreased to $10.8 million from $11.1 million year-over-year, while G&A expenses remained stable at $6.3 million. The company expects current cash to fund operations through Q2 2025.
Xilio Therapeutics (Nasdaq: XLO) announced it will present initial Phase 1C dose escalation data for XTX101 (vilastobart) in combination with atezolizumab at the SITC 39th Annual Meeting. The presentation will focus on results from patients with advanced solid tumors. The late-breaker poster session will take place on November 8, 2024, at the George R. Brown Convention Center in Houston, Texas. XTX101 is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody being developed for cancer treatment.
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place in Houston, Texas, from November 6-10, 2024.
The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format. The poster, titled "Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models," will be presented on Saturday, Nov. 9, 2024. The presentation will be available for viewing during the lunch and poster viewing session from 12:15 – 1:45 p.m. CST and during the poster reception from 7:10 – 8:40 p.m. CST at the George R. Brown Convention Center.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced the granting of stock options to three new employees. The Compensation Committee approved non-qualified stock options to purchase 101,000 shares of common stock under the company's 2022 Inducement Stock Incentive Plan. These options, effective October 1, 2024, have an exercise price of $0.75 per share, matching the closing price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employment.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.
Xilio Therapeutics (Nasdaq: XLO) reported Q2 2024 financial results and pipeline updates. Key highlights include:
1. Initiated Phase 2 trial of XTX101 with atezolizumab in MSS CRC patients.
2. Started Phase 1B monotherapy dose expansion for XTX301 in advanced solid tumors.
3. Expects to report clinical data for XTX101 and XTX301 in Q4 2024.
4. Q2 2024 ended with $74.9 million in cash, anticipating runway into Q2 2025.
5. Q2 2024 financial results: $2.4 million license revenue, $11.2 million R&D expenses, $5.8 million G&A expenses, $13.9 million net loss.
6. Promoted Chris Frankenfield to CFO while retaining COO role.
7. Advancing research-stage tumor-activated bispecifics and immune cell engagers.
Xilio Therapeutics, a clinical-stage biotechnology firm, has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors as of June 13, 2024.
Dr. Brennan brings over 16 years of industry leadership, having held executive roles at Synlogic and Biogen, while Dr. Shannon has over 30 years of experience, previously serving as chief medical officer at GlaxoSmithKline and holding leadership positions at Novartis.
Their extensive expertise is expected to significantly contribute to Xilio's ongoing development of novel, tumor-activated immuno-oncology therapies, with several clinical milestones anticipated in the near term.
Xilio Therapeutics (NASDAQ: XLO) announced significant pipeline and business updates alongside its Q1 2024 financial results. Highlighting their progress, they plan to initiate a Phase 2 trial for XTX101, an Fc-enhanced anti-CTLA-4, in combination with atezolizumab for MSS CRC in Q3 2024, and report clinical data in Q4 2024. The XTX301 IL-12 program, partnered with Gilead Sciences, received $43.5M upfront and is set for Phase 1 data release in Q4 2024. Furthermore, Xilio's research efforts on bispecifics and immune cell engagers are advancing. Financially, Xilio ended Q1 2024 with $34M in cash, supplemented by an additional $44.6M from Gilead agreements and private placements, projecting a cash runway until Q2 2025.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is Xilio Therapeutics, Inc.?
What does the name Xilio mean?
What are the key products developed by Xilio?
What is the focus of Xilio's technology platform?
What recent achievements has Xilio reported?
What is XTX202?
What is XTX101?
What is XTX301?
How can I learn more about Xilio Therapeutics?
What are the financial prospects of Xilio Therapeutics?
